Endocrine Society FDA Testimony on Biosimilars

The Future of Insulin Biosimilars: Increasing Access and Facilitating the Efficient Development of Insulin Biosimilar and Interchangeable Products

"The cost of insulin has nearly tripled in the past fifteen years, making it difficult for many of the over 7 million people who use insulin to afford this medication and effectively manage their diabetes. This has put patient safety in jeopardy as patient self-rationing of their insulin may lead to unnecessary hospitalizations, complications or death and should not be a costsavings approach that people with diabetes are forced to choose. The issue of insulin affordability is a top priority for the Endocrine Society and one we hear frequently about from our members, many of whom have conversations daily with their patients about their ability to afford their insulin..."

Read the Full Testimony

Policy Communications